B+
Bull case
25%
Probability
Target price
$195.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
NBIX
Neurocrine BiosciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
55%
Probability
Target price
$171.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$140.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
+70.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+73.2
Score
AI commentary
News tone is positive after Q2 revenue growth and the raised INGREZZA guidance. However, consensus surprise, post-print price reaction, analyst revisions, options data, short interest, employee sentiment, and social coverage are unavailable; missing data lowers conviction.
RankAlpha Sentiment Codex - 2026-08-08
Open full AI memoEvidence flagged
high-coverage report lacks a dated company-specific catalyst beyond generic cadence
Impact
tentative
Confidence
-
AI events
2026-07-30eventQ2 growth and raised INGREZZA guidance strengthen the operating baselineMedium impact
Q2 revenue grew 39% year over year to $959 million; INGREZZA sales were $716 million, and 2026 INGREZZA guidance increased to $2.825-$2.875 billion. [#SEC-8K-2026-07-30]
2026-11-06catalystVYKAT XR commercialization and Soleno integrationMedium impact
VYKAT XR generated $54 million from the May 18 acquisition close, versus $94 million on a pro forma full-quarter basis. Execution, reimbursement, and integration are the next checks. [#SEC-8K-2026-07-30]
2027-08-08catalystEstimated July 2027 osavampator Phase 3 data windowHigh impact
The company identified 2027 Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia. [#SEC-8K-2026-07-30] ClinicalTrials.gov lists estimated primary completion in July 2027 for Neurocrine-sponsored Phase 3 study NBI-1065845-MDD3026, providing a company-specific dated monitoring window: [ClinicalTrials.gov NCT06963021](https://clinicaltrials.gov/study/NCT06963021). Outcomes remain unproven.
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology